SIRT6 Protein Reverses Glioblastoma Drug Resistance Through Epigenetic Mechanism
Researchers discover how SIRT6 protein overcomes temozolomide resistance in deadly brain cancer by modifying histone lactylation patterns.
Summary
Scientists identified a breakthrough mechanism for overcoming drug resistance in glioblastoma, the deadliest brain cancer. They found that SIRT6, a longevity-associated protein, can reverse resistance to temozolomide chemotherapy by removing lactyl groups from histone H3K9, which suppresses the MGMT DNA repair gene. When combined with a SIRT6-activating compound called MDL-800, temozolomide became effective again in resistant cancer cells. This discovery reveals a new therapeutic target for treating drug-resistant glioblastoma through epigenetic modification.
Detailed Summary
Glioblastoma represents the most aggressive form of brain cancer, with over 50% of patients developing resistance to temozolomide, the standard chemotherapy treatment. This resistance severely limits treatment options and contributes to the cancer's devastating prognosis.
Researchers investigated the role of SIRT6, a NAD+-dependent deacetylase known for its longevity benefits, in temozolomide resistance. They discovered that nuclear SIRT6 deficiency characterizes drug-resistant glioblastoma cells, suggesting this protein plays a crucial protective role against resistance development.
The study revealed that SIRT6 works by removing lactyl modifications from histone H3K9, an epigenetic mechanism that suppresses transcription of the MGMT gene. MGMT encodes a DNA repair enzyme that removes temozolomide-induced DNA damage, making cancer cells resistant to treatment. By reducing H3K9 lactylation, SIRT6 keeps MGMT expression low, maintaining cancer cell sensitivity to chemotherapy.
When researchers enhanced SIRT6 activity using the compound MDL-800 combined with temozolomide, they observed significant tumor growth inhibition and increased cancer cell death in both laboratory and animal studies. Importantly, this therapeutic effect required SIRT6's translocation into the cell nucleus, where it can access and modify histones.
These findings establish the SIRT6-H3K9 lactylation-MGMT pathway as a targetable vulnerability for overcoming chemotherapy resistance. The research suggests that SIRT6 activators could serve as combination therapies to restore temozolomide effectiveness in resistant glioblastoma patients, potentially improving outcomes for this devastating disease.
Key Findings
- Nuclear SIRT6 deficiency characterizes temozolomide-resistant glioblastoma cells
- SIRT6 suppresses MGMT transcription by removing H3K9 lactylation modifications
- MDL-800 SIRT6 activator combined with temozolomide overcomes drug resistance
- Nuclear SIRT6 translocation is required for therapeutic effectiveness
- SIRT6-H3K9la-MGMT axis represents new therapeutic target for brain cancer
Methodology
The study used both in vitro cell culture experiments with temozolomide-resistant glioblastoma cell lines and in vivo animal models. Researchers examined SIRT6 expression patterns, tested the MDL-800 compound as a SIRT6 activator, and analyzed histone modifications through epigenetic assays.
Study Limitations
This summary is based on the abstract only, limiting detailed analysis of experimental methods and statistical significance. The research appears to be primarily preclinical, requiring further validation in human studies before clinical application.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.